We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+20.66%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.64B
AUM Growth
+$352M
Cap. Flow
-$18.8M
Cap. Flow %
-0.71%
Top 10 Hldgs %
38.92%
Holding
218
New
26
Increased
62
Reduced
55
Closed
4

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14M
2
JNJ icon
Johnson & Johnson
JNJ
+$13.4M
3
ABT icon
Abbott
ABT
+$12.5M
4
MIST icon
Milestone Pharmaceuticals
MIST
+$12.4M
5
CI icon
Cigna
CI
+$12M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$146M
2
UNH icon
UnitedHealth
UNH
+$23.1M
3
ISRG icon
Intuitive Surgical
ISRG
+$9.43M
4
HUM icon
Humana
HUM
+$9.27M
5
ZTS icon
Zoetis
ZTS
+$7.29M

Sector Composition

Rank Sector Weight
1 Healthcare 94.16%
2 Real Estate 3.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCEL
76
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$8.12M 0.31%
524,896
+357,651
+214% +$4.32M
MPT
77
Medical Properties Trust
MPT
$2.81B
$7.9M 0.3%
374,289
+187,226
+100% +$3.79M
TEVA icon
78
Teva Pharmaceuticals
TEVA
$41.2B
$7.7M 0.29%
785,851
– –
LTC
79
LTC Properties
LTC
$2.06B
$7.42M 0.28%
165,668
+20,247
+14% +$973K
ARGX icon
80
argenx
ARGX
$54.6B
$7.22M 0.27%
44,977
+10,929
+32% +$1.48M
STRO icon
81
Sutro Biopharma
STRO
$411M
$7.05M 0.27%
64,127
– –
SAGE
82
DELISTED
Sage Therapeutics
SAGE
$6.95M 0.26%
96,211
+9,431
+11% +$1.16M
SYNH
83
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$6.89M 0.26%
115,842
+69,860
+152% +$3.76M
ALLK
84
DELISTED
Allakos
ALLK
$6.81M 0.26%
71,396
+59,189
+485% +$5.2M
XRAY icon
85
Dentsply Sirona
XRAY
$2.75B
$6.78M 0.26%
119,736
-17,200
-13% -$959K
IOVA icon
86
Iovance Biotherapeutics
IOVA
$2.09B
$6.74M 0.25%
243,483
+68,471
+39% +$1.56M
ARWR icon
87
Arrowhead Research
ARWR
$12.3B
$6.68M 0.25%
105,398
+74,698
+243% +$3.71M
XBI icon
88
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$6.47M 0.24%
68,037
-20,985
-24% -$1.82M
ALGN icon
89
Align Technology
ALGN
$12.4B
$6.24M 0.24%
22,378
-5,900
-21% -$1.47M
AVDL
90
DELISTED
Avadel Pharmaceuticals
AVDL
$6.15M 0.23%
814,588
– –
NKTR icon
91
Nektar Therapeutics
NKTR
$2.41B
$6.12M 0.23%
18,912
– –
TFX icon
92
Teleflex
TFX
$5.86B
$5.88M 0.22%
15,608
+9,229
+145% +$3.18M
ZGNX
93
DELISTED
Zogenix, Inc.
ZGNX
$5.62M 0.21%
107,703
+45,629
+74% +$2.09M
ABMD
94
DELISTED
Abiomed Inc
ABMD
$5.58M 0.21%
32,716
– –
IQV icon
95
IQVIA
IQV
$39.1B
$5.53M 0.21%
35,815
+5,958
+20% +$870K
GRTX
96
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$5.48M 0.21%
+416,666
New +$5.08M
XLV icon
97
State Street Health Care Select Sector SPDR ETF
XLV
$42.2B
$5.48M 0.21%
+53,773
New +$5.17M
RETA
98
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.4M 0.2%
+26,412
New +$4.82M
LH icon
99
Labcorp
LH
$25.9B
$5.32M 0.2%
36,578
– –
PVLA
100
Palvella Therapeutics
PVLA
$2.15B
$5.25M 0.2%
18,116
– –
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Tekla Capital Management held 218 positions worth $2.64B, up 15% from $2.29B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q4 2019 filing shows 26 new, 62 increased, 55 reduced and 4 closed positions. Its largest new stake was Centene: 149,526 shares worth $9.4M. The largest sale was Celgene Corp, an estimated $146M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2019 buy was Centene: 149,526 shares worth $9.4M.
  • Tekla Capital Management added most to Regeneron Pharmaceuticals in Q4 2019, an estimated $14M increase.
  • Tekla Capital Management's biggest Q4 2019 reduction was UnitedHealth, cutting an estimated $23.1M.
  • Tekla Capital Management fully exited Celgene Corp in Q4 2019, selling an estimated $146M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.64B portfolio in Q4 2019.
  • Tekla Capital Management opened 26 new positions and closed 4 in Q4 2019.
  • Tekla Capital Management's portfolio value rose 15% quarter-over-quarter to $2.64B.

Based on Tekla Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.